Substantial rise in sparteine metabolic ratio during haloperidol treatment.
A sparteine test was carried out in 14 patients suffering from acute schizophrenic psychoses before and 1-2 times during oral haloperidol treatment in doses of 10-40 mg day-1. In patients classified as extensive metabolisers (sparteine MR less than 20 before treatment), haloperidol treatment resulted in a rise in sparteine MR that correlated with the serum-haloperidol concentration both within and between patients. At the highest serum haloperidol concentrations (60-80 nM) an increase in sparteine MR by a factor 15-50 was seen, but no patients were transformed into phenotypically poor metabolisers. The steady state concentration of haloperidol on the initial standard dose of 10 mg day-1 was the same in one patient classified as a sparteine poor metaboliser (MR = 112) as in eleven patients classified as extensive metabolisers (MR:0.22-1.47).
Gram
L F
LF
Centre Psychiatrique Esquirol, University Hospital Center of Caen, France.
Debruyne
D
D
Caillard
V
V
Boulenger
J P
JP
Lacotte
J
J
Moulin
M
M
Zarifian
E
E
D000328:Adult; D005260:Female; D006220:Haloperidol / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D013034:Sparteine / Q000378:metabolism*
D013034:Sparteine; D006220:Haloperidol